Sector News

KU Leuven, Batavia partner to develop Covid-19 vaccine candidate

December 6, 2020
Life sciences

KU Leuven in Belgium has partnered with contract development and manufacturing organisation, Batavia Biosciences, to develop a vector-based Covid-19 vaccine candidate.

The KU Leuven Rega Institute for Medical Research Virology research team, headed by Prof Dr Johan Neyts, developed a vaccine candidate with an attenuated vector carrying the SARS-CoV-2 spike immunogen.

The vector derives from the live-attenuated yellow fever vaccine (YF17D strain).

Currently named RegaVax, the YF17D-SARS-CoV-2 vaccine candidate demonstrated convincing immunogenicity and efficacy data in pre-clinical challenge studies.

Based on data, the research team intends to progress to the next phase of development, preparation for clinical trials.

To aid this process, KU Leuven joined forces with Batavia Biosciences.

Neyts said: “RegaVax is the only Covid-19 vaccine candidate based on the yellow fever vaccine. In preclinical models, for example with hamsters, one single dose appears to be highly efficient in protecting against infection with SARS-CoV-2.

“We hope that this vaccine, will, like the yellow fever vaccine on which it is based, provide, after a single dose, long-lasting protection against this coronavirus.”

Leveraging its vaccine development and manufacturing expertise along with HIP-Vax manufacturing technology, Batavia will develop a clinical manufacturing process for RegaVax, deliver clinical product and prepare for large-scale commercial supply.

Batavia Biosciences COO Dr Christopher Yallop said: “Our HIP-Vax technology is ideally suited to develop and manufacture this vaccine rapidly and cost-effectively and we are very much looking forward to working closely with the KU Leuven team to deliver the clinical product and help move this vaccine candidate to licensure.”

KU Leuven and Batavia Biosciences plan to deliver the clinical product and initiate clinical testing next year.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend